Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

[1]  R. Rudd,et al.  Malignant Mesothelioma , 2020, Definitions.

[2]  P. Baas,et al.  Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. , 2019, The Lancet. Respiratory medicine.

[3]  D. Planchard,et al.  Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.

[4]  M. Stockler,et al.  OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result , 2018, Journal of Thoracic Oncology.

[5]  A. D’Incecco,et al.  Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. , 2018, The Lancet. Respiratory medicine.

[6]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[7]  N. Le Stang,et al.  Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Albelda,et al.  Novel therapies for malignant pleural mesothelioma. , 2018, The Lancet. Oncology.

[9]  M. Slade,et al.  British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma , 2018, Thorax.

[10]  S. Armato,et al.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Socinski,et al.  Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[13]  K. Nackaerts,et al.  Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.

[14]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[15]  J. Aerts,et al.  Novel insights into mesothelioma biology and implications for therapy , 2017, Nature Reviews Cancer.

[16]  N. Pavlakis,et al.  Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression , 2017 .

[17]  T. Seiwert,et al.  Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial. , 2017 .

[18]  N. Le Stang,et al.  PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better? , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  P. Boutros,et al.  The Immune Microenvironment, Genome‐wide Copy Number Aberrations, and Survival in Mesothelioma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  A. Santoro,et al.  Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[21]  F. Galateau-Sallé,et al.  The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  P. Jänne,et al.  Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors , 2016, Cancer Immunology Research.

[23]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[24]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[25]  S. Durinck,et al.  Abstract LB-331: Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016 .

[26]  B. Milleron,et al.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[27]  David R. Jones,et al.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers , 2015, Oncoimmunology.

[28]  E. Felip,et al.  Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) , 2015, PloS one.

[29]  A. Mansfield,et al.  B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  C. Sima,et al.  Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients , 2011, Cancer Immunology, Immunotherapy.

[31]  M. Nishimura,et al.  CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.

[32]  R. Stahel,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  H. Dienemann,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[34]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  S. Gettinger,et al.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.

[36]  P. V. Van Schil,et al.  Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Kris,et al.  Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). , 1993, European journal of cancer.